cGMP Analogue Synthesis via Selective Crystallization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for synthesizing cyclic guanosine-3′, 5′-monophosphate (cGMP) analogues are laborious, require extensive chromatography for stereoisomer separation, and are limited to laboratory scales, lacking robustness and efficiency in producing high-purity intermediates and products.
Innovation Solution
A method involving the steps of providing a guanosine analogue, contacting it with a phosphorous oxoacid derivative to form a guanosine 5′-monophosphorous oxoacid ester analogue, which is then crystallized and used for subsequent cyclization to produce cGMP analogues, allowing for improved yield and stereoselectivity without the need for chromatographic separation, and enabling scalable production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If extensive chromatography is used for stereoisomer separation, then purity of cGMP analogues is improved, but productivity and ease of manufacture deteriorate due to laborious and time-consuming processes
Solution Approach 1:
The patent extracts and isolates the desired stereoisomer (Rp-isomer) from the reaction mixture through selective crystallization, removing the need for extensive chromatographic separation. The key intermediate H-phosphonate ester crystallizes selectively, allowing direct isolation of high-purity product without laborious chromatography.
Solution Approach 2:
The patent utilizes phase transition (crystallization) to separate stereoisomers. The H-phosphonate ester intermediate undergoes phase transition from dissolved state to crystalline state, enabling physical separation of the desired isomer from the reaction mixture and eliminating the need for chromatographic methods.
2Reliability
If conventional synthesis methods are used, then cGMP analogues can be produced, but the process is limited to laboratory scales and lacks robustness
Solution Approach 1:
The patent modifies reaction parameters including solvent selection (acetonitrile/water mixture), temperature control (0°C to room temperature), and pH adjustment to optimize the crystallization process. These parameter changes enable reliable scaling from laboratory to industrial production while maintaining high purity and stereoselectivity.
Solution Approach 2:
The patent performs preliminary optimization of the crystallization conditions and reaction parameters before scale-up. By establishing optimized protocols for the H-phosphonate ester formation and isolation at small scale, the method ensures robustness and reliability when transitioning to larger production scales.
3Manufacturing precision
If chromatographic separation is employed, then stereoisomers can be separated, but the process becomes laborious and time-consuming
Solution Approach 1:
The patent replaces time-consuming chromatographic separation with rapid crystallization-based separation. The selective crystallization of the H-phosphonate ester intermediate from the reaction mixture achieves stereoisomer separation in minutes rather than hours, dramatically reducing processing time while maintaining high purity.
Solution Approach 2:
The patent replaces the mechanical chromatographic separation system with a simpler crystallization-based separation method. Instead of using complex chromatography columns and solvents, the process relies on spontaneous crystallization and filtration, eliminating the need for sophisticated mechanical separation equipment and reducing operational complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enhances the yield and purity of cGMP analogues, enabling production on larger scales with improved stereoselectivity and eliminating the need for laborious chromatographic separation, resulting in high-purity products suitable for pharmaceutical applications.
Implementation Method 1
isolating the obtained guanosine 5′-monophosphorous oxoacid ester analogue by crystallization
Data Source
AI summary
The present invention relates to a method for preparing cyclic guanosine-3′, 5′-monophosphate analogues. The invention also relates to the new cyclic guanosine-monophosphate analogues and intermediates obtained by the method.